1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Diagnosis and Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 Non-Small Cell Lung Cancer
1.2.3 Small Cell Lung Cancer
1.3 Market by Application
1.3.1 Global Lung Cancer Diagnosis and Therapeutics Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Diagnosis and Therapeutics Market Perspective (2018-2030)
2.2 Lung Cancer Diagnosis and Therapeutics Growth Trends by Region
2.2.1 Lung Cancer Diagnosis and Therapeutics Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 Lung Cancer Diagnosis and Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Region (2023-2030)
2.3 Lung Cancer Diagnosis and Therapeutics Market Dynamics
2.3.1 Lung Cancer Diagnosis and Therapeutics Industry Trends
2.3.2 Lung Cancer Diagnosis and Therapeutics Market Drivers
2.3.3 Lung Cancer Diagnosis and Therapeutics Market Challenges
2.3.4 Lung Cancer Diagnosis and Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue
3.1.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Lung Cancer Diagnosis and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lung Cancer Diagnosis and Therapeutics Revenue
3.4 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio
3.4.1 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnosis and Therapeutics Revenue in 2022
3.5 Lung Cancer Diagnosis and Therapeutics Key Players Head office and Area Served
3.6 Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
3.7 Date of Enter into Lung Cancer Diagnosis and Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Diagnosis and Therapeutics Breakdown Data by Type
4.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Type (2023-2030)
5 Lung Cancer Diagnosis and Therapeutics Breakdown Data by Application
5.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
6.2 North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
6.3 North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
7.2 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
7.3 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
8.2 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
8.3 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
9.2 Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
9.3 Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
10.2 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
10.3 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Lung Cancer Diagnosis and Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Lung Cancer Diagnosis and Therapeutics Introduction
11.2.4 Eli Lilly Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.2.5 Eli Lilly Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Lung Cancer Diagnosis and Therapeutics Introduction
11.3.4 Sanofi Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 ArQule
11.4.1 ArQule Company Detail
11.4.2 ArQule Business Overview
11.4.3 ArQule Lung Cancer Diagnosis and Therapeutics Introduction
11.4.4 ArQule Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.4.5 ArQule Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Detail
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.5.5 Daiichi Sankyo Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Lung Cancer Diagnosis and Therapeutics Introduction
11.6.4 Celgene Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.6.5 Celgene Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Lung Cancer Diagnosis and Therapeutics Introduction
11.7.4 Merck Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.7.5 Merck Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Lung Cancer Diagnosis and Therapeutics Introduction
11.8.4 Pfizer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Detail
11.9.2 Boehringer Ingelheim Business Overview
11.9.3 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Introduction
11.9.4 Boehringer Ingelheim Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.9.5 Boehringer Ingelheim Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Lung Cancer Diagnosis and Therapeutics Introduction
11.10.4 Roche Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.10.5 Roche Recent Development
11.11 Genentech
11.11.1 Genentech Company Detail
11.11.2 Genentech Business Overview
11.11.3 Genentech Lung Cancer Diagnosis and Therapeutics Introduction
11.11.4 Genentech Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.11.5 Genentech Recent Development
11.12 GSK
11.12.1 GSK Company Detail
11.12.2 GSK Business Overview
11.12.3 GSK Lung Cancer Diagnosis and Therapeutics Introduction
11.12.4 GSK Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.12.5 GSK Recent Development
11.13 Pharmacyclics
11.13.1 Pharmacyclics Company Detail
11.13.2 Pharmacyclics Business Overview
11.13.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Introduction
11.13.4 Pharmacyclics Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.13.5 Pharmacyclics Recent Development
11.14 Novartis
11.14.1 Novartis Company Detail
11.14.2 Novartis Business Overview
11.14.3 Novartis Lung Cancer Diagnosis and Therapeutics Introduction
11.14.4 Novartis Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.14.5 Novartis Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Lung Cancer Diagnosis and Therapeutics Introduction
11.15.4 Bayer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.15.5 Bayer Recent Development
11.16 Bristol-Myers Squibb
11.16.1 Bristol-Myers Squibb Company Detail
11.16.2 Bristol-Myers Squibb Business Overview
11.16.3 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Introduction
11.16.4 Bristol-Myers Squibb Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.16.5 Bristol-Myers Squibb Recent Development
11.17 Eisai
11.17.1 Eisai Company Detail
11.17.2 Eisai Business Overview
11.17.3 Eisai Lung Cancer Diagnosis and Therapeutics Introduction
11.17.4 Eisai Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.17.5 Eisai Recent Development
11.18 AbbVie
11.18.1 AbbVie Company Detail
11.18.2 AbbVie Business Overview
11.18.3 AbbVie Lung Cancer Diagnosis and Therapeutics Introduction
11.18.4 AbbVie Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.18.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
